Skip to content

Enucleation and high-risk pathology

TL;DR — Enucleation remains definitive treatment for an eye that cannot be salvaged safely or usefully, especially when advanced disease, painful glaucoma or suspected invasion makes delay hazardous. The intact specimen provides the histopathology that determines systemic relapse risk: postlaminar optic-nerve, massive choroidal, scleral and extrascleral invasion carry different implications and combinations matter. Pre-enucleation chemotherapy can obscure pathology. Adjuvant treatment should be tied to defined features rather than to group E alone.

Decision-relevant evidence

  • High-risk pathology is common after primary enucleation and its distribution differs by continent. Across 1,426 primarily enucleated eyes from five continents, massive choroidal invasion occurred in 31% (Asia), 7% (Australia), 13% (Europe), 19% (North America) and 27% (South America) (P = 0.001) and postlaminar optic-nerve invasion in 27%, 0%, 16%, 21% and 19% (P = 0.0006); adjuvant chemotherapy with or without orbital radiotherapy was given to 53%. Six-year orbital recurrence was 5%, 2%, 0%, 0% and 12% (P < 0.001), metastasis 8%, 5%, 2%, 0% and 13% (P = 0.001) and death 10%, 3%, 2%, 0% and 11% (P < 0.001) (Kaliki 2024, PMID 39151183).

  • Which eyes carry high-risk features is partly predictable clinically: 145 of 403 primarily enucleated Asian Indian eyes (36%) had high-risk features, occurring in 39% of group E but 16% of group D eyes; the commonest features were postlaminar optic-nerve invasion (49%), massive choroidal invasion (48%), anterior-chamber seeds (17%), scleral infiltration (14%), ciliary-body infiltration (12%) and combined choroidal plus optic-nerve invasion (12%), with a median of two features per eye (range 1–7) (Kaliki 2015, PMID 25841975).

  • In isolated massive choroidal invasion, adjuvant chemotherapy was associated with five-year relapse-free survival 97.2% versus 55.6% and overall survival 97.2% versus 66.7% (both P < 0.001) among 60 children with no other high-risk feature; three children needed treatment to prevent one relapse or death. The comparison is observational and 80% of the cohort received chemotherapy, so confounding by indication remains possible (Feng 2023, PMID 37603354).

  • Choroidal invasion alone may not be the lethal variable. In a SEER analysis of 393 patients, massive choroidal invasion carried higher all-cause mortality (HR 41.29, 95% CI 4.05–420.49, P = 0.002) while focal invasion did not (HR 2.69, 0.17–43.09, P = 0.484) — but all four cancer-related deaths occurred in patients with massive choroidal invasion and concomitant postlaminar optic-nerve invasion, whose five-year survival was 80.2% against 100% for massive choroidal invasion without it (Loya 2023, PMID 36610585). The extremely wide confidence interval reflects six deaths in total.

  • For postlaminar optic-nerve invasion the effect size is large. Across 292 patients from nine countries with postlaminar invasion after primary enucleation, those who received no adjuvant chemotherapy (n = 16) had orbital recurrence in 31% versus 2% (P < 0.001), metastasis in 31% versus 6% (P = 0.001) and death in 38% versus 9% (P = 0.007), with subhazard ratios of 19.31 (95% CI 5.56–67.05) for orbital recurrence and 5.39 (1.75–16.60) for metastasis; in isolated postlaminar invasion the metastasis subhazard ratio reached 40.68 (9.65–171.55, P < 0.001) (Lin 2026, PMID 41475682). Only 16 patients went untreated, so the untreated arm is small and non-randomly selected.

  • The historical comparison points the same way: of 80 unilateral high-risk eyes managed 1974–1999, metastasis occurred in 10 (13%) at median 9 months, and 8 of those 10 had received no adjuvant therapy (Honavar 2002, PMID 12096963).

  • A prospective cooperative-group study defined the low-risk boundary. Among 321 enucleated unilateral cases with central histopathology review, two-year event-free survival was 0.96 (95% CI 0.89–0.98) for those with high-risk features who received chemotherapy and 0.99 (0.96–1.0) for those observed without high-risk features. Central review disagreed with the contributing institution in 23% of high-risk and 17% of non-high-risk cases, and concomitant focal (<3 mm) choroidal with prelaminar/laminar optic-nerve invasion showed no recurrences (Chévez-Barrios 2019, PMID 31539297).

  • That reviewer disagreement is not an isolated finding. In 600 children from 14 centres in nine countries, 505 (84.2%) were locally called high-risk and given adjuvant chemotherapy; after median 39.2 months, 6.0% had orbital recurrence, 8.2% metastasis and 12.0% died, and children not given adjuvant chemotherapy were at significantly higher risk of all three (P ≤ .002). Applying a standardised definition reclassified cases that centres had locally called non-high-risk (Arazi 2024, PMID 39332513). The survey evidence explains why: only postlaminar optic-nerve invasion, transection involvement and extrascleral infiltration were called high-risk by all 27 responding specialists, while minor choroidal invasion reached only 19% agreement (Kaliki 2022, PMID 34762098).

  • How long adjuvant therapy should run is now answered for one defined population: a randomized 187-patient trial found three CEV cycles noninferior to six for enucleated unilateral disease with massive choroidal infiltration, retrolaminar optic-nerve invasion or scleral infiltration, with five-year disease-free survival 90.4% versus 89.2% (difference 1.2%, 95% CI −7.5 to 9.8) and fewer adverse events, less quality-of-life loss and lower cost in the shorter arm (Ye 2024, PMID 39432296).

  • Risk-stratified protocols that withhold adjuvant therapy from pT1/pT2a disease appear safe in prospective observation: among 184 primarily enucleated children, 71% were low-risk and received no adjuvant treatment, 26.0% were intermediate (pT2b/pT3) and 2.7% high-risk (pT4). No pT1–pT3 child relapsed — two-year progression-free and overall survival 100% — while two of five pT4 children had extraocular relapse and one died (Diarra 2023, PMID 40061040).

  • Older regimens achieved comparable control at higher toxicity cost. Post-enucleation cyclophosphamide, vincristine, doxorubicin and intrathecal methotrexate in 20 unilateral high-risk patients (90% group E, 95% with optic-nerve involvement) gave 100% overall and 95% event-free survival over median 102 months, with one secondary rhabdomyosarcoma at 99.6 months (Sunwoo 2022, PMID 36553426); an earlier 36-patient adjuvant series using vincristine, doxorubicin and cyclophosphamide reported five metastatic deaths, all in children with massive tumours and choroidal or optic-nerve margin involvement (Mustafa 1999, PMID 10524448).

  • Primary and secondary enucleation carry similar overall high-risk-feature prevalence but different patterns: in 121 eyes, primarily enucleated eyes more often had massive choroidal invasion (P = 0.0315) and postlaminar optic-nerve invasion (P = 0.027) while secondarily enucleated eyes more often had anterior-chamber invasion (P = 0.013); overall prevalence was 35.5% versus 37.5% (P = 0.585) with no difference in metastasis or survival (Mohammad 2023, PMID 36760120).

  • Enucleation is a surgical and rehabilitative pathway, not a single event: an orbital implant is usually placed, and perioperative care is shaped by the child's age and by the parent or caregiver who manages recovery (Leclerc 2020, PMID 31886534).

Clinical and research frame

Domain Operational meaning Evidence boundary
Massive choroidal invasion Systemic dissemination risk Definition and isolated versus combined feature matter
Postlaminar optic-nerve invasion Higher risk Margin involvement is more severe
Scleral/extrascleral invasion Advanced pathologic extent Escalated staging and therapy
Pre-enucleation chemotherapy May downstage/alter histology Document timing
Socket/prosthesis Rehabilitation and growth Not a cosmetic afterthought

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
37603354 2023 Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma. Topic-resolved source (Feng 2023, PMID 37603354)
39432296 2024 Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. Topic-resolved source (Ye 2024, PMID 39432296)
34762098 2022 Defining High-risk Retinoblastoma: A Multicenter Global Survey. Topic-resolved source (Kaliki 2022, PMID 34762098)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
41475682 2026 Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion: A Global Multicenter Study. Topic-resolved source (Lin 2026, PMID 41475682)
39922380 2025 High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes. Topic-resolved source (Kurian 2025, PMID 39922380)
36553426 2022 Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma. Topic-resolved source (Sunwoo 2022, PMID 36553426)
39332513 2024 Treatment Outcomes and Definition Inconsistencies in High-Risk Unilateral Retinoblastoma. Topic-resolved source (Arazi 2024, PMID 39332513)
40061040 2023 Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastoma. Topic-resolved source (Diarra 2023, PMID 40061040)
12096963 2002 Postenucleation adjuvant therapy in high-risk retinoblastoma. Topic-resolved source (Honavar 2002, PMID 12096963)
39151183 2024 HIGH-RISK HISTOPATHOLOGICAL FEATURES OF RETINOBLASTOMA FOLLOWING PRIMARY ENUCLEATION: A Global Study Of 1,426 Patients From 5 Continents. Topic-resolved source (Kaliki 2024, PMID 39151183)
17076529 2006 Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Topic-resolved source (Chong 2006, PMID 17076529)
21721113 2012 Clinical predictors of high risk histopathology in retinoblastoma. Topic-resolved source (Kashyap 2012, PMID 21721113)
36760120 2023 A comparison of high risk pathological features between primary and secondary enucleation for retinoblastoma. Topic-resolved source (Mohammad 2023, PMID 36760120)
15258027 2004 Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Topic-resolved source (Chantada 2004, PMID 15258027)
10524448 1999 Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. Topic-resolved source (Mustafa 1999, PMID 10524448)
28302322 2017 High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes. Topic-resolved source (Fabian 2017, PMID 28302322)
28834944 2018 HIGH-RISK INTRAOCULAR RETINOBLASTOMA: Comparison Between Asian Indians and Americans From Two Major Referral Centers. Topic-resolved source (Kaliki 2018, PMID 28834944)
25841975 2015 Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Topic-resolved source (Kaliki 2015, PMID 25841975)
25583279 2015 Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre. Topic-resolved source (Künkele 2015, PMID 25583279)
31539297 2019 Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. Topic-resolved source (Chévez-Barrios 2019, PMID 31539297)
33720495 2021 Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). Topic-resolved source (Dittner-Moormann 2021, PMID 33720495)
31536438 2019 Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. Topic-resolved source (Luna-Fineman 2019, PMID 31536438)
27806788 2016 [Treatment and prognostic analysis of retinoblastoma patients with choroid invasion]. Topic-resolved source (Wang 2016, PMID 27806788)
39731391 2025 Impact of Race on the Outcomes of Retinoblastoma Treated With Primary Enucleation: A Global Study of 1426 Patients. Topic-resolved source (Kaliki 2025, PMID 39731391)
29043448 2017 [Retinoblastoma and retinocytoma (retinoma)]. Topic-resolved source (Metz 2017, PMID 29043448)
36170219 2022 Controversies in the Management of Choroidal Invasion in Retinoblastoma. Topic-resolved source (Pendri 2022, PMID 36170219)
38492167 2024 Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Singh 2024, PMID 38492167)
38730450 2024 Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression. Topic-resolved source (Tang 2024, PMID 38730450)
36610585 2023 Association of choroidal invasion with retinoblastoma survival rates. Topic-resolved source (Loya 2023, PMID 36610585)
40177152 2025 Liver metastasis of retinoblastoma. Topic-resolved source (Apumayta 2025, PMID 40177152)
41129126 2025 Spatial Proteomic Analysis Highlights Molecular Reprogramming in Optic Nerve Invasive Retinoblastoma. Topic-resolved source (Zhu 2025, PMID 41129126)
38815108 2025 Ophthalmic Artery Chemosurgery for Optic Nerve Invasion in Retinoblastoma. Topic-resolved source (Abramson 2025, PMID 38815108)
33383259 2021 Successful Treatment of Massive Choroidal Invasion in Retinoblastoma with Intra-arterial Chemotherapy (Ophthalmic Artery Chemosurgery). Topic-resolved source (Abramson 2021, PMID 33383259)
40993896 2025 Angiogenesis Signaling in Retinoblastoma: Prognostic and Therapeutic Applications. Topic-resolved source (Yang 2025, PMID 40993896)
35996791 2021 Multidisciplinary Approach for Retinoblastoma Management. Topic-resolved source (Thakur 2021, PMID 35996791)
41043969 2025 High-risk features in retinoblastoma: the association between histopathology and MRI. Topic-resolved source (Kheir 2025, PMID 41043969)
42397330 2026 Multimodal Imaging of Optic Nerve Invasion in Unilateral Retinoblastoma. Topic-resolved source (Koenig 2026, PMID 42397330)
29915463 2018 Standard reporting of high-risk histopathology features in retinoblastoma. Topic-resolved source (Thaung 2018, PMID 29915463)
29915470 2018 Standard reporting of high-risk histopathology features in retinoblastoma. Topic-resolved source (Thaung 2018, PMID 29915470)
31886534 2020 An Overview of Retinoblastoma and Enucleation in Pediatric Patients. Added by audit 2026-09-01 (Leclerc 2020, PMID 31886534)

Source chronology

Era marker PMID What the record contributes
1999 10524448 Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. (Mustafa 1999, PMID 10524448)
2002 12096963 Postenucleation adjuvant therapy in high-risk retinoblastoma. (Honavar 2002, PMID 12096963)
2004 15258027 Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? (Chantada 2004, PMID 15258027)
2006 17076529 Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. (Chong 2006, PMID 17076529)
2012 21721113 Clinical predictors of high risk histopathology in retinoblastoma. (Kashyap 2012, PMID 21721113)
2015 25583279 Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre. (Künkele 2015, PMID 25583279)
2015 25841975 Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. (Kaliki 2015, PMID 25841975)
2016 27806788 [Treatment and prognostic analysis of retinoblastoma patients with choroid invasion]. (Wang 2016, PMID 27806788)
2017 28302322 High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes. (Fabian 2017, PMID 28302322)
2017 29043448 [Retinoblastoma and retinocytoma (retinoma)]. (Metz 2017, PMID 29043448)
2018 28834944 HIGH-RISK INTRAOCULAR RETINOBLASTOMA: Comparison Between Asian Indians and Americans From Two Major Referral Centers. (Kaliki 2018, PMID 28834944)
2018 29915463 Standard reporting of high-risk histopathology features in retinoblastoma. (Thaung 2018, PMID 29915463)
2018 29915470 Standard reporting of high-risk histopathology features in retinoblastoma. (Thaung 2018, PMID 29915470)
2019 31536438 Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. (Luna-Fineman 2019, PMID 31536438)
2019 31539297 Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. (Chévez-Barrios 2019, PMID 31539297)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Which isolated pathology features truly require chemotherapy? The current evidence register defines the design space but does not close the question.

  • Can pathology central review reduce treatment variation? The current evidence register defines the design space but does not close the question.

  • What prosthetic and orbital-growth outcomes follow modern implant strategies? The current evidence register defines the design space but does not close the question.

References

  1. Feng ZX, et al. Adjuvant Chemotherapy Improves Survival for Children With Massive Choroidal Invasion of Retinoblastoma. Investigative ophthalmology & visual science. 2023;64:27. PMID 37603354
  2. Ye H, et al. Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. JAMA. 2024;332:1634-1641. PMID 39432296
  3. Kaliki S, et al. Defining High-risk Retinoblastoma: A Multicenter Global Survey. JAMA ophthalmology. 2022;140:30-36. PMID 34762098
  4. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  5. Lin M, et al. Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion: A Global Multicenter Study. Ophthalmology. Retina. 2026;10:562-572. PMID 41475682
  6. Kurian DE, et al. High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes. Ophthalmology. Retina. 2025;9:787-797. PMID 39922380
  7. Sunwoo Y, et al. Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma. Children (Basel, Switzerland). 2022;9. PMID 36553426
  8. Arazi M, et al. Treatment Outcomes and Definition Inconsistencies in High-Risk Unilateral Retinoblastoma. American journal of ophthalmology. 2024;268:399-408. PMID 39332513
  9. Diarra Y, et al. Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastoma. EJC paediatric oncology. 2023;1:None. PMID 40061040
  10. Honavar SG, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Archives of ophthalmology (Chicago, Ill. : 1960). 2002;120:923-31. PMID 12096963
  11. Kaliki S, et al. HIGH-RISK HISTOPATHOLOGICAL FEATURES OF RETINOBLASTOMA FOLLOWING PRIMARY ENUCLEATION: A Global Study Of 1,426 Patients From 5 Continents. Retina (Philadelphia, Pa.). 2024;44:2105-2115. PMID 39151183
  12. Chong EM, et al. Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Archives of pathology & laboratory medicine. 2006;130:1669-72. PMID 17076529
  13. Kashyap S, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatric blood & cancer. 2012;58:356-61. PMID 21721113
  14. Mohammad M, et al. A comparison of high risk pathological features between primary and secondary enucleation for retinoblastoma. European journal of ophthalmology. 2023;33:2014-2023. PMID 36760120
  15. Chantada GL, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? The British journal of ophthalmology. 2004;88:1069-73. PMID 15258027
  16. Mustafa MM, et al. Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. Journal of pediatric hematology/oncology. 1999;21:364-9. PMID 10524448
  17. Fabian ID, et al. High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes. Ophthalmology. 2017;124:851-858. PMID 28302322
  18. Kaliki S, et al. HIGH-RISK INTRAOCULAR RETINOBLASTOMA: Comparison Between Asian Indians and Americans From Two Major Referral Centers. Retina (Philadelphia, Pa.). 2018;38:2023-2029. PMID 28834944
  19. Kaliki S, et al. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology. 2015;122:1165-72. PMID 25841975
  20. Künkele A, et al. Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre. The British journal of ophthalmology. 2015;99:949-53. PMID 25583279
  21. Chévez-Barrios P, et al. Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:2883-2891. PMID 31539297
  22. Dittner-Moormann S, et al. Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). Pediatric blood & cancer. 2021;68:e28963. PMID 33720495
  23. Luna-Fineman S, et al. Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:2875-2882. PMID 31536438
  24. Wang YZ, et al. [Treatment and prognostic analysis of retinoblastoma patients with choroid invasion]. Zhonghua er ke za zhi = Chinese journal of pediatrics. 2016;54:819-822. PMID 27806788
  25. Kaliki S, et al. Impact of Race on the Outcomes of Retinoblastoma Treated With Primary Enucleation: A Global Study of 1426 Patients. Clinical & experimental ophthalmology. 2025;53:421-434. PMID 39731391
  26. Metz KA, et al. [Retinoblastoma and retinocytoma (retinoma)]. Der Pathologe. 2017;38:507-514. PMID 29043448
  27. Pendri PR, et al. Controversies in the Management of Choroidal Invasion in Retinoblastoma. International ophthalmology clinics. 2022;62:27-37. PMID 36170219
  28. Singh L, et al. Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1147-1156. PMID 38492167
  29. Tang J, et al. Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression. Biomarker research. 2024;12:48. PMID 38730450
  30. Loya A, et al. Association of choroidal invasion with retinoblastoma survival rates. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2023;27:32.e1-32.e8. PMID 36610585
  31. Apumayta ED, et al. Liver metastasis of retinoblastoma. Ecancermedicalscience. 2025;19:1824. PMID 40177152
  32. Zhu T, et al. Spatial Proteomic Analysis Highlights Molecular Reprogramming in Optic Nerve Invasive Retinoblastoma. Investigative ophthalmology & visual science. 2025;66:37. PMID 41129126
  33. Abramson DH, et al. Ophthalmic Artery Chemosurgery for Optic Nerve Invasion in Retinoblastoma. Journal of pediatric ophthalmology and strabismus. 2025;62:150. PMID 38815108
  34. Abramson DH, et al. Successful Treatment of Massive Choroidal Invasion in Retinoblastoma with Intra-arterial Chemotherapy (Ophthalmic Artery Chemosurgery). Ophthalmology. Retina. 2021;5:936-939. PMID 33383259
  35. Yang E, et al. Angiogenesis Signaling in Retinoblastoma: Prognostic and Therapeutic Applications. International ophthalmology clinics. 2025;65:35-41. PMID 40993896
  36. Thakur S, et al. Multidisciplinary Approach for Retinoblastoma Management. Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH. 2021;13:234-236. PMID 35996791
  37. Kheir WJ, et al. High-risk features in retinoblastoma: the association between histopathology and MRI. BMJ open ophthalmology. 2025;10. PMID 41043969
  38. Koenig LR, et al. Multimodal Imaging of Optic Nerve Invasion in Unilateral Retinoblastoma. Ophthalmology. 2026. PMID 42397330
  39. Thaung C, et al. Standard reporting of high-risk histopathology features in retinoblastoma. Community eye health. 2018;31:17. PMID 29915463
  40. Thaung C, et al. Standard reporting of high-risk histopathology features in retinoblastoma. Community eye health. 2018;31:31-33. PMID 29915470
  41. Leclerc R, et al. An Overview of Retinoblastoma and Enucleation in Pediatric Patients. AORN journal. 2020;111:69-79. PMID 31886534